Associated tags: Patient, Physician, Indegene
Locations: KANSAS CITY, KS, SINGAPORE, USA, ISRAEL, PRINCETON, NJ, US, NEW JERSEY, UK, GERMANY
PRINCETON, N.J., April 02, 2024 (GLOBE NEWSWIRE) -- Indegene, a digital-first, life sciences commercialization company, hosted its first Strategic Advisory Board (SAB) meeting recently in New Jersey, chaired by Jill DeSimone, a well-known biopharma leader, with over four decades of global experience.
Key Points:
- PRINCETON, N.J., April 02, 2024 (GLOBE NEWSWIRE) -- Indegene, a digital-first, life sciences commercialization company, hosted its first Strategic Advisory Board (SAB) meeting recently in New Jersey, chaired by Jill DeSimone, a well-known biopharma leader, with over four decades of global experience.
- She has previously worked with industry giants such as Bristol Myers Squibb, and Teva, and was the President of US Oncology at Merck.
- Under Jill's leadership, the SAB aims to propel Indegene's market and customer growth by infusing outside expertise, perspective, and thought leadership.
- "The Strategic Advisory Board will be pivotal to Indegene’s success, signifying our commitment to growth and innovation”, said Gaurav Kapoor, Executive Vice President, Indegene.
Synthetic media,
Neuroscience,
Growth,
Urology,
Partnership,
Knowledge,
Acquisition,
Health Canada,
Immunology,
Investment,
Safety,
PMDA,
Trilogy,
Endocrinology,
Generative PRINCETON, N.J. and FRANKFURT, Germany, March 27, 2024 (GLOBE NEWSWIRE) -- Indegene, a digital-first, life sciences commercialization company, announced the acquisition of Trilogy Writing & Consulting GmbH (Trilogy), a global provider of specialty medical writing capabilities across clinical, regulatory, safety and medical content to life sciences companies.
Key Points:
- PRINCETON, N.J. and FRANKFURT, Germany, March 27, 2024 (GLOBE NEWSWIRE) -- Indegene, a digital-first, life sciences commercialization company, announced the acquisition of Trilogy Writing & Consulting GmbH (Trilogy), a global provider of specialty medical writing capabilities across clinical, regulatory, safety and medical content to life sciences companies.
- The acquisition by Indegene Ireland, a subsidiary of Indegene Limited, augments Indegene’s depth of clinical and regulatory writing expertise for market authorization applications globally.
- Trilogy Writing & Consulting is a Germany, UK, and US-based, medical writing consultancy with know-how in the development and delivery of clinical, regulatory, safety, and medical content.
- It applies its expertise and unique approaches to deliver quality medical writing output.
Retrieved on:
Wednesday, March 27, 2024
Seyfarth Shaw,
Synthetic media,
Neuroscience,
Growth,
Urology,
Partnership,
Knowledge,
Acquisition,
Health Canada,
Immunology,
Investment,
Safety,
PMDA,
Trilogy,
Endocrinology,
Generative PRINCETON, N.J. and FRANKFURT, Germany, March 27, 2024 (GLOBE NEWSWIRE) -- Indegene, a digital-first, life sciences commercialization company, announced the acquisition of Trilogy Writing & Consulting GmbH (Trilogy), a global provider of specialty medical writing capabilities across clinical, regulatory, safety and medical content to life sciences companies.
Key Points:
- PRINCETON, N.J. and FRANKFURT, Germany, March 27, 2024 (GLOBE NEWSWIRE) -- Indegene, a digital-first, life sciences commercialization company, announced the acquisition of Trilogy Writing & Consulting GmbH (Trilogy), a global provider of specialty medical writing capabilities across clinical, regulatory, safety and medical content to life sciences companies.
- The acquisition by Indegene Ireland, a subsidiary of Indegene Limited, augments Indegene’s depth of clinical and regulatory writing expertise for market authorization applications globally.
- Trilogy Writing & Consulting is a Germany, UK, and US-based, medical writing consultancy with know-how in the development and delivery of clinical, regulatory, safety, and medical content.
- It applies its expertise and unique approaches to deliver quality medical writing output.
Retrieved on:
Wednesday, January 24, 2024
Synthetic media,
PEAK,
Practice,
Drug discovery,
Mount Everest,
Generative,
Investment,
ROI,
GTM,
Center of excellence,
Management PRINCETON, N.J., Jan. 24, 2024 (GLOBE NEWSWIRE) -- Everest Group, a leading global research and consulting firm, has recognized Indegene as a Leader in its Life Sciences Digital Services Specialist PEAK Matrix® Assessment 2024.
Key Points:
- PRINCETON, N.J., Jan. 24, 2024 (GLOBE NEWSWIRE) -- Everest Group, a leading global research and consulting firm, has recognized Indegene as a Leader in its Life Sciences Digital Services Specialist PEAK Matrix® Assessment 2024.
- Durga Ambati, Practice Director at Everest Group, said, “The current macroeconomic uncertainties have pushed life sciences enterprises to rethink their digital transformation strategy, thus prioritizing investments that ensure better RoI over speculative, transformational bets.
- Clients have commended its collaborative approach and the overall proactiveness and agility, hence earning it a Leader position in Life Sciences Digital Services Specialists PEAK Matrix® Assessment 2024,” added Durga.
- Everest Group’s Life Sciences Digital Services Specialist PEAK Matrix® Assessment 2024 focused exclusively on life sciences specialist service providers.
Retrieved on:
Monday, November 20, 2023
PRINCETON, N.J., Nov. 20, 2023 (GLOBE NEWSWIRE) -- HFS, a leading global research and analysis firm, recognizes Indegene as a Market Leader in the HFS Horizons: Life Sciences Service Providers, 2023 report.
Key Points:
- PRINCETON, N.J., Nov. 20, 2023 (GLOBE NEWSWIRE) -- HFS, a leading global research and analysis firm, recognizes Indegene as a Market Leader in the HFS Horizons: Life Sciences Service Providers, 2023 report.
- “Increasingly, life sciences companies are turning to specialist service providers with deep domain knowledge and contemporary technology capabilities to help them accelerate their digital transformation”, said Gaurav Kapoor, EVP, Indegene.
- “HFS Research’s recognition validates our clients’ trust in our team to bring these capabilities together and enable them to improve health outcomes for all.”
The HFS Horizons: Life Sciences Service Providers, 2023 report examined the role and capabilities of 29 leading service providers across the global life sciences industry.
- The report specifically focuses on the domain-specific capabilities of these service providers across many dimensions, spanning value proposition, innovation capabilities, go-to-market strategy, and market impact.
Retrieved on:
Thursday, September 14, 2023
PRINCETON, N.J., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Indegene, a digital-first, life sciences commercialization company, announced the fifth edition of Indegene Digital Summit, the annual flagship event for global life sciences leaders, on September 21 - 22, 2023.
Key Points:
- PRINCETON, N.J., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Indegene, a digital-first, life sciences commercialization company, announced the fifth edition of Indegene Digital Summit, the annual flagship event for global life sciences leaders, on September 21 - 22, 2023.
- This exclusive thought leadership virtual event will see thought-provoking strategic discussions pertinent to the commercialization functions of the life sciences value chain.
- The summit brings a power-packed lineup of thought leaders from within and beyond the life sciences industry on a single platform to exchange views on the future of commercialization.
- The leaders will discuss the role of technology paradigms such as Generative AI in transforming traditional commercialization models.
PRINCETON, N.J., Aug. 22, 2023 (GLOBE NEWSWIRE) -- Indegene, a digital-first, life sciences commercialization company today announced the launch of Invisage [in-vis-ij], an AI-enabled proprietary platform to help life sciences organizations optimize their go-to-market model.
Key Points:
- PRINCETON, N.J., Aug. 22, 2023 (GLOBE NEWSWIRE) -- Indegene, a digital-first, life sciences commercialization company today announced the launch of Invisage [in-vis-ij], an AI-enabled proprietary platform to help life sciences organizations optimize their go-to-market model.
- Invisage helps deliver personalized outcomes to healthcare professionals (HCPs) by leveraging data from over 2 million HCP and more than 200 million HCP interactions.
- Invisage is an integrated hybrid omnichannel platform that brings together data, AI-driven scientific modeling, and strategic insights to deploy digital campaigns and partner digital channels with a sales force to expand HCP reach and optimize interactions.
- “We are excited to introduce Invisage to the market and enable life sciences companies to effectively reach HCPs, powered by Indegene’s AI-driven platform and our team of experts,” said Nancy Phelan, Senior Vice President, Omnichannel Activation, Indegene.
Tissue,
CE,
Medicine,
Partnership,
Pelvic organ prolapse,
Failure,
Senior,
Marketing,
Pharmacovigilance,
Woman,
POP1,
HCP,
Pelvic floor,
Prolapse,
US,
Provat Lakra,
FDA,
POP,
US FDA,
Birth control,
Medical device,
Pharmaceutical industry,
Indegene ConTIPI Medical’s mission is to help women suffering from Pelvic Organ Prolapse (POP).
Key Points:
- ConTIPI Medical’s mission is to help women suffering from Pelvic Organ Prolapse (POP).
- The US FDA states that POP occurs when the pelvic floor’s tissues and muscles can no longer support its organs which causes a drop or prolapse of the pelvic organs.
- Approximately 54 million American women over 20 years old suffer from POP1.
- Bourne Partners served as the exclusive financial advisor to ConTIPI Medical.
Survivor,
Senior,
Education,
Marketing,
Stroke,
TBI,
EMG,
Ageing,
Rehabilitation,
Learning,
Brain damage,
Pain,
Occupational therapy,
Patient,
EEG,
Neuro,
Synergy,
Medical imaging,
Pharmaceutical industry SynPhNe has developed the world’s first connected wearable solution that trains brain and muscle in one system.
Key Points:
- SynPhNe has developed the world’s first connected wearable solution that trains brain and muscle in one system.
- It is designed to help stroke survivors and patients with disabilities recover and lead more independent lives.
- The traumatic brain injury market is also growing with more than 69 million people worldwide sustaining a TBI each year2.
- To help them get better access to effective treatment, we are excited to work with Indegene to bring our treatment option to the market.
KANSAS CITY, Kan., May 12, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that Cingulate Chairman & CEO Shane J. Schaffer, and Timothy Moore, Indegene Senior Vice President, Emerging Biotech, will participate in a live Benzinga All Access event on Monday May 15, 2023, at 10 a.m. CST.
Key Points:
- KANSAS CITY, Kan., May 12, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that Cingulate Chairman & CEO Shane J. Schaffer, and Timothy Moore, Indegene Senior Vice President, Emerging Biotech, will participate in a live Benzinga All Access event on Monday May 15, 2023, at 10 a.m. CST.
- The discussion will focus on the recent announcement of a joint commercialization agreement between Cingulate and Indegene , a life sciences commercialization company, to provide commercial support for Cingulate’s lead candidate CTx-1301 (dexmethylphenidate), a novel, investigational treatment being developed as a true, once-daily stimulant medication for attention deficit/hyperactivity disorder (ADHD), upon approval from the U.S. Food and Drug Administration (FDA).
- The event may be viewed live on Benzinga’s YouTube channel, Benzinga All Access , and will also be available for viewing on Cingulate’s website at cingulate.com/investors .
